Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Altimmune (ALT) Change in Accured Expenses (2016 - 2025)

Altimmune (ALT) has disclosed Change in Accured Expenses for 16 consecutive years, with $102000.0 as the latest value for Q3 2025.

  • On a quarterly basis, Change in Accured Expenses rose 102.15% to $102000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $408000.0, a 138.53% increase, with the full-year FY2024 number at -$112000.0, up 94.05% from a year prior.
  • Change in Accured Expenses was $102000.0 for Q3 2025 at Altimmune, up from -$365000.0 in the prior quarter.
  • In the past five years, Change in Accured Expenses ranged from a high of $11.0 million in Q3 2021 to a low of -$9.2 million in Q4 2021.
  • A 5-year average of -$45421.1 and a median of -$1.5 million in 2022 define the central range for Change in Accured Expenses.
  • Peak YoY movement for Change in Accured Expenses: surged 835.0% in 2021, then plummeted 392.0% in 2024.
  • Altimmune's Change in Accured Expenses stood at -$9.2 million in 2021, then skyrocketed by 76.54% to -$2.2 million in 2022, then surged by 165.82% to $1.4 million in 2023, then skyrocketed by 66.55% to $2.4 million in 2024, then crashed by 95.7% to $102000.0 in 2025.
  • Per Business Quant, the three most recent readings for ALT's Change in Accured Expenses are $102000.0 (Q3 2025), -$365000.0 (Q2 2025), and -$1.7 million (Q1 2025).